Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. 由 Croucher, P, Hijzen, A, Shipman, C, Perry, M, Lippitt, J, Green, J, Van Camp, B, Vanderkerken, K

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma 由 Croucher, P, De Raeve, H, Perry, M, Hijzen, A, Shipman, C, Lippitt, J, Green, J, Van Marck, E, Van Camp, B, Vanderkerken, K

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased su... 由 Croucher, P, De Hendrik, R, Perry, M, Hijzen, A, Shipman, C, Lippitt, J, Green, J, Van Marck, E, Van Camp, B, Vanderkerken, K

Zoledronic acid prevents the development of myeloma bone disease and increases survival 由 Shipman, C, Vanderkerken, K, De Raeve, H, Perry, M, Hijzen, A, Lippitt, J, Green, J, Van Marck, E, Van Camp, B, Croucher, P

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. 由 Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K